TY - JOUR
AU - T'Sjoen, Guy
AB - 172 Letters to the Editor 4. Hatzimouratidis K, Eardley I, Giuliano F, et alEuropean Associ- 5. Ralph D, Gonzalez-Cadavid N, Mirone V, et al. The management ation of Urology. EAU guidelines on penile curvature. Eur Urol of Peyronie’s disease: evidence-based 2010 guidelines. J Sex 2012;62:543-552. Med 2010;7:2359-2374. Concerning the Article by Fung et al, Titled “Differential Effects of Cyproterone Acetate vs Spironolactone on Serum High-Density Lipoprotein and Prolactin Concentrations in the Hormonal Treatment of Transgender Women” Fung et al stated that the observed increased serum prolactin female reference ranges (with a higher upper level of normal levels in trans women are caused by the administration of values); thus, far fewer participants would be diagnosed with cyproterone acetate (CPA) and cannot be attributed solely to hyperprolactinemia. the use of estrogens, contrary to popular belief. In their study, Therefore, we suggest that, in the absence of symptoms there was a mild (þ11.8 mg/L) increase in prolactin after suggestive for a prolactinoma, it is sufficient to obtain serum initiation of CPA therapy (from 8.5 mg/L at baseline to 19.7 prolactin levels at baseline, because CPA causes only a mild and mg/L after 12 months), whereas the increase in serum prolactin transient increase 
TI - Concerning the Article by Fung et al, Titled “Differential Effects of Cyproterone Acetate vs Spironolactone on Serum High-Density Lipoprotein and Prolactin Concentrations in the Hormonal Treatment of Transgender Women”
JO - The Journal of Sexual Medicine
DO - 10.1016/j.jsxm.2016.10.014
DA - 2017-01-01
UR - https://www.deepdyve.com/lp/oxford-university-press/concerning-the-article-by-fung-et-al-titled-differential-effects-of-PMYqKiT01A
SP - 172
EP - 173
VL - 14
IS - 1
DP - DeepDyve
ER -